Cologuard: not Exact enough?
This article was originally published in Clinica
Exact Sciences’ share price took a beating last week after a pivotal study of its Cologuard colorectal cancer screening test met its primary and secondary endpoints, but fell short on the detection of precancerous polyps. The stool-based DNA test looks for mutations associated with cancer and precancerous conditions, and is based on the principle that cancers and polyps shed cells into the stool stream.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.